Tarceva and Conjunctivitis - a phase IV clinical study of FDA data

Summary:

Conjunctivitis is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Xanax, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Conjunctivitis when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Conjunctivitis?

Conjunctivitis (pink eye) is found to be associated with 1,299 drugs and 1,639 conditions by eHealthMe. Check the latest studies of Conjunctivitis.

On Jul, 08, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 88 people (0.29%) have Conjunctivitis.

Among these 88 people:

How long have people been on Tarceva when they have Conjunctivitis? *

What is the gender of people who have Conjunctivitis when taking Tarceva? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Conjunctivitis when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides Conjunctivitis? *

Rashes (redness): 40 people, 45.45%
Diarrhea: 31 people, 35.23%
Dermatitis Acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis): 16 people, 18.18%
Fatigue (feeling of tiredness): 14 people, 15.91%
Skin Exfoliation (removal of the oldest dead skin cells): 8 people, 9.09%
Eye Pain: 7 people, 7.95%
Nausea (feeling of having an urge to vomit): 7 people, 7.95%
Nosebleed (bleeding from nose): 7 people, 7.95%
Dry Skin: 7 people, 7.95%
Nausea And Vomiting: 7 people, 7.95%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 39 people, 44.32%
Malignant Respiratory Tract Neoplasm (cancer tumour of respiratory tract): 4 people, 4.55%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 4 people, 4.55%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 4 people, 4.55%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 2.27%
Lung Cancer Metastatic (lung cancer spreads to other parts): 2 people, 2.27%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 2.27%
Type 2 Diabetes: 2 people, 2.27%
Neoplasm Malignant (cancer tumour): 1 person, 1.14%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 1.14%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Conjunctivitis?

- Check whether Conjunctivitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Conjunctivitis treatments and more:

Conjunctivitis (22,439 reports)

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis:

Conjunctivitis (1,299 drugs)

Browse all the conditions that are associated with Conjunctivitis:

Conjunctivitis (1,639 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.